These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18398059)

  • 1. Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.
    Portell C; Nand S
    Blood; 2008 Apr; 111(8):4416-7. PubMed ID: 18398059
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder.
    Läubli H; Tzankov A; Juskevicius D; Degen L; Rochlitz C; Stenner-Liewen F
    Leuk Lymphoma; 2016; 57(4):945-8. PubMed ID: 26295731
    [No Abstract]   [Full Text] [Related]  

  • 3. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete response of age-related Epstein-Barr virus-associated polymorphic nodal lymphoproliferative disease of plasmacytic type to low-dose lenalidomide.
    Hwang YY; Au-Yeung R; Lau HP; Kwong YL
    Ann Hematol; 2018 Feb; 97(2):363-366. PubMed ID: 29063179
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of lenalidomide in treating refractory prurigo nodularis.
    Liu H; Gaspari AA; Schleichert R
    J Drugs Dermatol; 2013 Mar; 12(3):360-1. PubMed ID: 23545923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of prurigo nodularis with lenalidomide.
    Ossorio-García L; Jiménez-Gallo D; Rodríguez-Mateos ME; Arjona-Aguilera C; Linares-Barrios M
    Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27891738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
    Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
    Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions.
    Nahmias Z; Nambudiri VE; Vleugels RA
    J Am Acad Dermatol; 2016 Jul; 75(1):210-2. PubMed ID: 27317516
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide - current understanding of mechanistic properties.
    Tageja N
    Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.
    Mortensen TB; Frederiksen H; Marcher CW; Preiss B
    BMJ Case Rep; 2017 Jan; 2017():. PubMed ID: 28052942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of refractory prurigo nodularis with lenalidomide.
    Kanavy H; Bahner J; Korman NJ
    Arch Dermatol; 2012 Jul; 148(7):794-6. PubMed ID: 22801610
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
    Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunomodulatory effects of lenalidomide].
    Handa H; Saitoh T; Murakami H
    Nihon Rinsho; 2015 Jan; 73(1):156-61. PubMed ID: 25626322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.
    Dreicer R
    Curr Oncol Rep; 2007 Mar; 9(2):120-3. PubMed ID: 17288877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.
    Ramsay AG; Gribben JG
    Haematologica; 2009 Sep; 94(9):1198-202. PubMed ID: 19734414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.